Abstract
Introduction: The study presents current views on the pharmacotherapy of community-acquired pneumonia (CAP). This study also describes in general terms the current pharmacoepidemiological situation of the CAP in Russia and abroad, which can both help medical professionals make an informed choice when choosing a pharmacotherapy, and inspire them to follow-up research and observations.
 The aim of the study is to conduct an analysis of the available research on the pharmacotherapy of CAP in order to accelerate the accumulation and assimilation of knowledge in the field of this pathology.
 Materials and methods: The following databases of medical publications and electronic libraries were used to search for the relevant sources of information: PubMed, Medline, Google Scholar, Crossref, and eLIBRARY.RU.
 Results and discussion: The choice of a rational antimicrobial therapy (AMT) for CAP is of high relevance due to the widespread of the pathology. The article highlights modern approaches to the pharmacotherapy of CAP in adults, including a review of promising new drugs, and presents the main problematic issues related to the emergence of antibiotic resistance of pathogens, as well as methods to combat it.
 Conclusion: The analyzed and generalized results of the conducted research allow the authors to make a conclusion about the feasibility of a more detailed study and raising the level of awareness of medical professionals in this pathology.
Highlights
The study presents current views on the pharmacotherapy of community-acquired pneumonia (CAP)
Most pulmonary societies claim that patients with mild and moderate forms of CAP can be treated by oral drugs, either at hospital or on an outpatient basis, and if tablets cannot be taken, parenteral pharmacotherapy is recommended
The pharmacotherapy duration should be increased if the initial empirical therapy has no effect against a specific pathogen or if pneumonia is complicated by an extrapulmonary infection
Summary
The study presents current views on the pharmacotherapy of community-acquired pneumonia (CAP). This study describes in general terms the current pharmacoepidemiological situation of the CAP in Russia and abroad, which can both help medical professionals make an informed choice when choosing a pharmacotherapy, and inspire them to follow-up research and observations. Of patients with a severe disease increases annually; mortality increases Studies in this area are actively conducted in almost all countries of the world (Ambaras Khan and Aziz 2018; ERRATUM 2019b). The improved care of patients with CAP in South Africa is especially important due to the high incidence rate and the need to improve antibiotic prescribing standards in the face of increasing antibiotic resistance. According to the statistical report on the state of mortality in South Africa, influenza and CAP together were ranked sixth among the leading causes of death in 2015 (Athlin et al 2018; Skinner et al 2018)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
